• Cerebral has announced a new transformation program for the company, which will focus on growth and patient experience, named “Cerebral Core.” The program involves objectives for reviewing quality practices while enhancing user and clinician experiences. 

• The company also plans on launching insurance offerings for payments, reviewing its clinical and marketing practices, growing its substance use disorder programs, increasing the number of tools available to clinicians, and building out its platform.

• Additionally, Walmart and CVS announced that they would stop filling prescriptions for controlled substances issued by Cerebral and telepsychiatry platform Done Health. Walmart’s decision follows an audit and compliance process review of Cerebral, while CVS also declined fulfillment of prescriptions issued by the two companies after they failed to resolve concerns raised. 

<ul><li>These announcements follow a string of news relating to Cerebral regarding its prescription requirements being too lenient ; it pausing new prescriptions , then halting all prescriptions following formal investigations into its practices ; and its CEO being replaced .</ul>